Integra Lifesciences Holdings (IART) Free Cash Flow (2009 - 2026)

Integra Lifesciences Holdings' Free Cash Flow history runs 18 years deep, the most recent figure standing at -$5.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 87.44% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at $4.1 million (up 126.32% YoY), while the FY2025 annual figure was -$31.1 million, down 224.39% from the prior year.
• Free Cash Flow came in at -$5.0 million for Q1 2026 at Integra Lifesciences Holdings, up from -$5.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $70.9 million in Q4 2022 to a low of -$40.2 million in Q1 2025.
• A 5-year average of $16.7 million and a median of $12.7 million in 2023 frame the typical range for Free Cash Flow.
• On a YoY basis, Free Cash Flow climbed as much as 459.59% in 2025 and fell as far as 13906.53% in 2025.
• Integra Lifesciences Holdings' Free Cash Flow stood at $70.9 million in 2022, then plunged by 51.73% to $34.2 million in 2023, then slumped by 38.21% to $21.1 million in 2024, then plunged by 125.53% to -$5.4 million in 2025, then gained by 6.54% to -$5.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$5.0 million, -$5.4 million, and $25.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison